Worcester HIV Vaccine

DNA Vaccine Shows Promise in Preventing HIV Infection

9 months ago

• A novel polyvalent DNA/prime-protein boost HIV vaccine (PDPHV) has demonstrated robust immunogenicity in a Phase I clinical trial. • The PDPHV vaccine elicited strong and cross-reactive immune responses against multiple HIV subtypes, showing superior results compared to previous HIV vaccines. • Researchers isolated a novel human monoclonal antibody (HmAb64) from a vaccinated participant, capable of neutralizing HIV isolates across subtypes. • The HmAb64 antibody targets the CD4 binding site on HIV, a challenging but critical target for HIV vaccine development.